Pronova BioPharma ASA

Pronova BioPharma ASA Pronova BioPharma ASA reports record-high second quarter results, with 34.3 per cent revenue growth and 23.5 per cent EBITDA growth. Global end-user sales were up 55 per cent to USD 283.3 million (May YTD), driven by market share growth in the USA. The blockbuster potential of the company's product is highlighted by a global run-rate in May 2008 of some USD 735 million (USD 475 million in May 2007).

Pronova BioPharma ASA 29 July, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) will publish the group's second quarter results on Tuesday 5 August 2008.

Pronova BioPharma ASA Please find enclosed the presentation of Pronova BioPharma ASA to be held on 28 May at the 13th Annual Carnegie Nordic Health Care Seminar in Stockholm, and on 29 May at the UBS Global Specialty Pharmaceutical and Generics Conference in London.